ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Emtriva 200 mg hard capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each hard capsule contains 200 mg emtricitabine.

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Hard capsule.

Each capsule has a white opaque body with a light blue opaque cap. Each capsule is printed with “200 mg” on the cap and “GILEAD” and [Gilead logo] on the body in black ink.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Emtriva is indicated for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents.

This indication is based on studies in treatment-naïve patients and treatment-experienced patients with stable virological control. There is no experience of the use of Emtriva in patients who are failing their current regimen or who have failed multiple regimens (see section 5.1).

When deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate.

4.2 Dosage and method of administration

Therapy should be initiated by a physician experienced in the management of HIV infection.

Emtriva 200 mg hard capsules may be taken with or without food.

Adults: The recommended dose of Emtriva is one 200 mg hard capsule, taken orally, once daily.

Children and adolescents up to 18 years of age: The recommended dose of Emtriva for children and adolescents weighing at least 33 kg who are able to swallow hard capsules is one 200 mg hard capsule, taken orally, once daily.

There are no data regarding the efficacy and only very limited data regarding the safety of emtricitabine in infants below 4 months of age. Therefore Emtriva is not recommended for use in those aged less than 4 months. (For pharmacokinetic data in this age group, see section 5.2).

Emtriva is also available as a 10 mg/ml oral solution for use in infants older than 4 months of age, children and patients who are unable to swallow hard capsules and patients with renal insufficiency. Please refer to the Summary of Product Characteristics for Emtriva 10 mg/ml oral solution. Due to a difference in the bioavailability of emtricitabine between the hard capsule and oral solution presentations, 240 mg emtricitabine administered as the oral solution should provide similar plasma
levels to those observed after administration of one 200 mg emtricitabine hard capsule (see section 5.2).

**Elderly:** There are no safety and efficacy data available in patients over the age of 65 years. However, no adjustment in the recommended daily dose for adults should be required unless there is evidence of renal insufficiency.

**Renal insufficiency:** Emtricitabine is eliminated by renal excretion and exposure to emtricitabine was significantly increased in patients with renal insufficiency (see section 5.2). Dose or dose interval adjustment is required in all patients with creatinine clearance < 50 ml/min (see section 4.4).

Table 1 below provides dose interval adjustment guidelines for the 200 mg hard capsules according to the degree of renal insufficiency. The safety and efficacy of these dose interval adjustment guidelines have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in these patients (see section 4.4).

Patients with renal insufficiency can also be managed by administration of Emtriva 10 mg/ml oral solution to provide a reduced daily dose of emtricitabine. Please refer to the Summary of Product Characteristics for Emtriva 10 mg/ml oral solution.

### Table 1: Dose interval guidelines for 200 mg hard capsules adjusted according to creatinine clearance

<table>
<thead>
<tr>
<th>Creatinine Clearance (CLcr) (ml/min)</th>
<th>≥ 50</th>
<th>30-49</th>
<th>15-29</th>
<th>&lt; 15 (functionally anephric, requiring intermittent haemodialysis)*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommended dose interval for 200 mg hard capsules</strong></td>
<td>One 200 mg hard capsule every 24 hours</td>
<td>One 200 mg hard capsule every 48 hours</td>
<td>One 200 mg hard capsule every 72 hours</td>
<td>One 200 mg hard capsule every 96 hours</td>
</tr>
</tbody>
</table>

* Assumes a 3 h haemodialysis session three times a week commencing at least 12 h after administration of the last dose of emtricitabine.

Patients with end-stage renal disease (ESRD) managed with other forms of dialysis such as ambulatory peritoneal dialysis have not been studied and no dose recommendations can be made.

No data are available on which to make a dosage recommendation in paediatric patients with renal insufficiency.

**Hepatic insufficiency:** No data are available on which to make a dose recommendation for patients with hepatic insufficiency. However, based on the minimal metabolism of emtricitabine and the renal route of elimination it is unlikely that a dose adjustment would be required in patients with hepatic insufficiency (see section 5.2).

If Emtriva is discontinued in patients co-infected with HIV and HBV, these patients should be closely monitored for evidence of exacerbation of hepatitis (see section 4.4).

### 4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients.
4.4 Special warnings and precautions for use

Emtriva should not be taken with any other medicinal products containing emtricitabine or medicinal products containing lamivudine.

General: Emtricitabine is not recommended as monotherapy for the treatment of HIV infection. It must be used in combination with other antiretrovirals. Please also refer to the Summaries of Product Characteristics of the other antiretroviral medicinal products used in the combination regimen.

Patients receiving emtricitabine or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.

Patients should be advised that antiretroviral therapies, including emtricitabine, have not been proven to prevent the risk of transmission of HIV to others through sexual contact or blood contamination. Appropriate precautions should continue to be used. Patients should also be informed that emtricitabine is not a cure for HIV infection.

Renal function: Emtricitabine is principally eliminated by the kidney via glomerular filtration and active tubular secretion. Emtricitabine exposure may be markedly increased in patients with moderate or severe renal insufficiency (creatinine clearance < 50 ml/min) receiving daily doses of 200 mg emtricitabine as hard capsules or 240 mg as the oral solution. Consequently, either a dose interval adjustment (using Emtriva 200 mg hard capsules) or a reduction in the daily dose of emtricitabine (using Emtriva 10 mg/ml oral solution) is required in all patients with creatinine clearance < 50 ml/min. The safety and efficacy of the dose interval adjustment guidelines provided in section 4.2 are based on single dose pharmacokinetic data and modelling and have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in patients treated with emtricitabine at prolonged dosing intervals (see sections 4.2 and 5.2).

Caution should be exercised when emtricitabine is co-administered with medicinal products that are eliminated by active tubular secretion as such co-administration may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product, due to competition for this elimination pathway (see section 4.5).

Lactic acidosis: Lactic acidosis, usually associated with hepatic steatosis, has been reported with the use of nucleoside analogues. Early symptoms (symptomatic hyperlactataemia) include benign digestive symptoms (nausea, vomiting and abdominal pain), non-specific malaise, loss of appetite, weight loss, respiratory symptoms (rapid and/or deep breathing) or neurological symptoms (including motor weakness). Lactic acidosis has a high mortality and may be associated with pancreatitis, liver failure or renal failure. Lactic acidosis generally occurred after a few or several months of treatment.

Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactataemia and metabolic/lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.

Caution should be exercised when administering nucleoside analogues to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease and hepatic steatosis (including certain medicinal products and alcohol). Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.

Patients at increased risk should be followed closely.

Lipodystrophy: Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV patients. The long-term consequences of these events are currently unknown. Knowledge about the mechanism is incomplete. A connection between visceral lipomatosis and protease inhibitors, and lipoatrophy and nucleoside reverse transcriptase inhibitors has
been hypothesised. A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances. Clinical examination should include evaluation for physical signs of fat redistribution. Consideration should be given to the measurement of fasting serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate.

**Liver function:** Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. Patients with chronic hepatitis B or C infection treated with combination antiretroviral therapy are at increased risk of experiencing severe, and potentially fatal, hepatic adverse events. In case of concomitant antiviral therapy for hepatitis B or C, please also refer to the relevant Summary of Product Characteristics for these medicinal products.

If there is evidence of exacerbations of liver disease in such patients, interruption or discontinuation of treatment must be considered.

**Patients co-infected with hepatitis B virus (HBV):** Emtricitabine is active *in vitro* against HBV. However, limited data are available on the efficacy and safety of emtricitabine (as a 200 mg hard capsule once daily) in patients who are co-infected with HIV and HBV. The use of emtricitabine in patients with chronic HBV induces the same mutation pattern in the YMDD motif observed with lamivudine therapy. The YMDD mutation confers resistance to both emtricitabine and lamivudine.

Patients co-infected with HIV and HBV should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment with emtricitabine for evidence of exacerbations of hepatitis. Such exacerbations have been seen following discontinuation of emtricitabine treatment in HBV infected patients without concomitant HIV infection and have been detected primarily by serum alanine aminotransferase (ALT) elevations in addition to re-emergence of HBV DNA. In some of these patients, HBV reactivation was associated with more severe liver disease, including decompensation and liver failure. There is insufficient evidence to determine whether re-initiation of emtricitabine alters the course of post-treatment exacerbations of hepatitis. In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbations of hepatitis may lead to hepatic decompensation.

**Mitochondrial dysfunction:** Nucleoside and nucleotide analogues have been demonstrated *in vitro* and *in vivo* to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in HIV negative infants exposed *in utero* and/or postnatally to nucleoside analogues. The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlactataemia, hyperlipasaemia). These events are often transitory. Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). Whether the neurological disorders are transient or permanent is currently unknown. Any child exposed *in utero* to nucleoside and nucleotide analogues, even HIV negative children, should have clinical and laboratory follow-up and should be fully investigated for possible mitochondrial dysfunction in case of relevant signs or symptoms. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.

**Immune Reactivation Syndrome:** In HIV infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and *Pneumocystis jirovecii* pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.

**Osteonecrosis:** Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). Patients should be advised to seek medical advice if they
experience joint aches and pain, joint stiffness or difficulty in movement.

4.5 Interaction with other medicinal products and other forms of interaction

*In vitro*, emtricitabine did not inhibit metabolism mediated by any of the following human CYP450 isoforms: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4. Emtricitabine did not inhibit the enzyme responsible for glucuronidation. Based on the results of these *in vitro* experiments and the known elimination pathways of emtricitabine, the potential for CYP450 mediated interactions involving emtricitabine with other medicinal products is low.

There are no clinically significant interactions when emtricitabine is co-administered with indinavir, zidovudine, stavudine, famciclovir or tenofovir disoproxil fumarate.

Emtricitabine is primarily excreted via glomerular filtration and active tubular secretion. With the exception of famciclovir and tenofovir disoproxil fumarate, the effect of co-administration of emtricitabine with medicinal products that are excreted by the renal route, or other medicinal products known to affect renal function, has not been evaluated. Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product due to competition for this elimination pathway.

There is no clinical experience as yet on the co-administration of cytidine analogues. Consequently, the use of emtricitabine in combination with lamivudine or zalcitabine for the treatment of HIV infection cannot be recommended at this time.

4.6 Pregnancy and lactation

The safety of emtricitabine in human pregnancy has not been established.

Animal studies do not indicate direct or indirect harmful effects of emtricitabine with respect to pregnancy, foetal development, parturition or postnatal development (see section 5.3).

Emtricitabine should be used during pregnancy only if necessary.

Given that the potential risks to developing human foetuses are unknown, the use of emtricitabine in women of childbearing potential must be accompanied by the use of effective contraception.

It is not known if emtricitabine is excreted in human milk.

It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, patients should be informed that dizziness has been reported during treatment with emtricitabine.

4.8 Undesirable effects

a. Summary of the safety profile

In clinical trials of HIV infected adults, the most frequently occurring adverse reactions to emtricitabine were diarrhoea (14.0%), headache (10.2%), elevated creatine kinase (10.2%) and nausea (10.0%). In addition to the adverse reactions reported in adults, anaemia (9.5%) and skin discolouration (31.8%) occurred more frequently in clinical trials involving HIV infected paediatric patients.

Lactic acidosis, severe hepatomegaly with steatosis and lipodystrophy are associated with
emtricitabine (see sections 4.4 and 4.8c).

Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump) (see section 4.4).

Discontinuation of Emtriva therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis (see section 4.4).

b. Tabulated summary of adverse reactions

Assessment of adverse reactions from clinical study data is based on experience in three studies in adults (n=1,479) and three paediatric studies (n=169). In the adult studies, 1,039 treatment-naive and 440 treatment-experienced patients received emtricitabine (n=814) or comparator medicinal product (n=665) for 48 weeks in combination with other antiretroviral medicinal products.

The adverse reactions with suspected (at least possible) relationship to treatment in adults from clinical trial and post-marketing experience are listed in Table 2 below by body system organ class and frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10) or uncommon (≥ 1/1,000 to < 1/100).

**Table 2: Tabulated summary of adverse reactions associated with emtricitabine based on clinical study and post-marketing experience**

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Emtricitabine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and lymphatic system disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>neutropenia</td>
</tr>
<tr>
<td>Uncommon:</td>
<td>anaemia</td>
</tr>
<tr>
<td><strong>Immune system disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>allergic reaction</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>hypertriglyceridaemia, hyperglycaemia</td>
</tr>
<tr>
<td><strong>Psychiatric disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>insomnia, abnormal dreams</td>
</tr>
<tr>
<td><strong>Nervous system disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Very common:</td>
<td>headache</td>
</tr>
<tr>
<td>Common:</td>
<td>dizziness</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Very common:</td>
<td>diarrhoea, nausea</td>
</tr>
<tr>
<td>Common:</td>
<td>elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal pain, dyspepsia</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>elevated serum aspartate aminotransferase (AST) and/or elevated serum alanine aminotransferase (ALT), hyperbilirubinaemia</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discoloration (increased pigmentation)</td>
</tr>
<tr>
<td>Uncommon:</td>
<td>angioedema</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Very common:</td>
<td>elevated creatine kinase</td>
</tr>
</tbody>
</table>
General disorders and administration site conditions:

| Common: asthenia, pain |

1 See section c. Description of selected adverse reactions for more details.
2 Anaemia was common and skin discoloration (increased pigmentation) was very common when emtricitabine was administered to paediatric patients (see section d.).
3 This adverse reaction, which was identified through post-marketing surveillance, was not observed in randomised, controlled clinical trials in adults or paediatric HIV clinical trials of emtricitabine. The frequency category of uncommon was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in these clinical studies (n=1,563).

c. Description of selected adverse reactions

Skin discoloration (increased pigmentation): Skin discoloration, manifested by hyperpigmentation mainly on the palms and/or soles, was generally mild, asymptomatic and of little clinical significance. The mechanism is unknown.

Lipids, lipodystrophy and metabolic abnormalities: Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).

Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump) (see section 4.4).

Immune Reactivation Syndrome: In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise (see section 4.4).

Osteonecrosis: Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). The frequency of this is unknown (see section 4.4).

Lactic acidosis and severe hepatomegaly with steatosis: Lactic acidosis, usually associated with hepatic steatosis, has been reported with the use of nucleoside analogues (see section 4.4).

d. Paediatric population

Assessment of adverse reactions in paediatric patients from clinical study data is based on experience in three paediatric studies (n=169) where treatment-naïve (n=123) and treatment-experienced (n=46) paediatric HIV infected patients aged 4 months to 18 years were treated with emtricitabine in combination with other antiretroviral agents.

In addition to the adverse reactions reported in adults (see section b.), the following adverse reactions were observed more frequently in paediatric patients: anaemia was common (9.5%) and skin discoloration (increased pigmentation) was very common (31.8%) in paediatric patients.

e. Other special population(s)

Elderly: Emtriva has not been studied in patients over the age of 65. Elderly patients are more likely to have decreased renal function, therefore caution should be exercised when treating elderly patients with Emtriva (see section 4.2).

Patients with renal impairment: Emtricitabine is eliminated by renal excretion and exposure to emtricitabine was significantly increased in patients with renal insufficiency. Dose or dose interval adjustment is required in all patients with creatinine clearance < 50 ml/min (see sections 4.2, 4.4 and 5.2).

HIV/HBV co-infected patients: The adverse reaction profile in patients co-infected with HBV is similar to that observed in patients infected with HIV without co-infection with HBV. However, as
would be expected in this patient population, elevations in AST and ALT occurred more frequently than in the general HIV infected population.

*Exacerbations of hepatitis after discontinuation of treatment:* In HIV infected patients co-infected with HBV, exacerbations of hepatitis may occur after discontinuation of treatment (see section 4.4).

### 4.9 Overdose

Administration of up to 1,200 mg emtricitabine has been associated with the adverse reactions listed above (see section 4.8).

If overdose occurs, the patient should be monitored for signs of toxicity and standard supportive treatment applied as necessary.

Up to 30% of the emtricitabine dose can be removed by haemodialysis. It is not known whether emtricitabine can be removed by peritoneal dialysis.

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1 Pharmacodynamic properties

*Pharmacotherapeutic group:* Nucleoside and nucleotide reverse transcriptase inhibitors, ATC code: J05AF09.

*Mechanism of action:* Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to human immunodeficiency virus (HIV-1 and HIV-2) and hepatitis B virus (HBV).

Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competitively inhibits HIV-1 reverse transcriptase, resulting in DNA chain termination. Emtricitabine is a weak inhibitor of mammalian DNA polymerase α, β and ε and mitochondrial DNA polymerase γ.

Emtricitabine did not exhibit cytotoxicity to peripheral blood mononuclear cells (PBMCs), established lymphocyte and monocyte-macrophage cell lines or bone marrow progenitor cells in vitro. There was no evidence of toxicity to mitochondria in vitro or in vivo.

*Antiviral activity in vitro:* The 50% inhibitory concentration (IC₅₀) value for emtricitabine against laboratory and clinical isolates of HIV-1 was in the range of 0.0013 to 0.5 µmol/l. In combination studies of emtricitabine with protease inhibitors, nucleoside, nucleotide and non-nucleoside analogue inhibitors of HIV reverse transcriptase, additive to synergistic effects were observed. Most of these combinations have not been studied in humans.

When tested for activity against laboratory strains of HBV, the 50% inhibitory concentration (IC₅₀) value for emtricitabine was in the range of 0.01 to 0.04 µmol/l.

*Resistance:* HIV-1 resistance to emtricitabine develops as the result of changes at codon 184 causing the methionine to be changed to a valine (an isoleucine intermediate has also been observed) of the HIV reverse transcriptase. This HIV-1 mutation was observed in vitro and in HIV-1 infected patients.

Emtricitabine-resistant viruses were cross-resistant to lamivudine, but retained sensitivity to other nucleoside reverse transcriptase inhibitors (NRTIs) (zidovudine, stavudine, tenofovir, abacavir, didanosine and zalcitabine), all non-nucleoside reverse transcriptase inhibitors (NNRTIs) and all protease inhibitors (PIs). Viruses resistant to zidovudine, zalcitabine, didanosine and NNRTIs retained their sensitivity to emtricitabine (IC₅₀=0.002 µmol/l to 0.08 µmol/l).

*Clinical experience:* Emtricitabine in combination with other antiretroviral agents, including nucleoside analogues, non-nucleoside analogues and protease inhibitors, has been shown to be
effective in the treatment of HIV infection in treatment-naïve patients and treatment-experienced patients with stable virological control. There is no experience of the use of emtricitabine in patients who are failing their current regimen or who have failed multiple regimens. There is no clinical experience of the use of emtricitabine in infants less than 4 months of age.

In antiretroviral treatment-naïve adults, emtricitabine was significantly superior to stavudine when both medicinal products were taken in combination with didanosine and efavirenz through 48 weeks of treatment. Phenotypic analysis showed no significant changes in emtricitabine susceptibility unless the M184V/I mutation had developed.

In virologically stable treatment-experienced adults, emtricitabine, in combination with an NRTI (either stavudine or zidovudine) and a protease inhibitor (PI) or an NNRTI was shown to be non-inferior to lamivudine with respect to the proportion of responders (< 400 copies/ml) through 48 weeks (77% emtricitabine, 82% lamivudine). Additionally, in a second study, treatment-experienced adults on a stable PI based highly active antiretroviral therapy (HAART) regimen were randomised to a once daily regimen containing emtricitabine or to continue with their PI-HAART regimen. At 48 weeks of treatment the emtricitabine-containing regimen demonstrated an equivalent proportion of patients with HIV RNA < 400 copies/ml (94% emtricitabine versus 92%) and a greater proportion of patients with HIV RNA < 50 copies/ml (95% emtricitabine versus 87%) compared with the patients continuing with their PI-HAART regimen.

In infants and children older than 4 months, the majority of patients achieved or maintained complete suppression of plasma HIV-1 RNA through 48 weeks (89% achieved ≤ 400 copies/ml and 77% achieved ≤ 50 copies/ml).

5.2 Pharmacokinetic properties

Absorption: Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose. In 20 HIV infected subjects receiving 200 mg emtricitabine daily as hard capsules, steady-state plasma emtricitabine peak concentrations (Cmax), trough concentrations (Cmin) and area under the plasma concentration time curve over a 24-hour dosing interval (AUC) were 1.8±0.7 µg/ml, 0.09±0.07 µg/ml and 10.0±3.1 µg·h/ml, respectively. Steady-state trough plasma concentrations reached levels approximately 4-fold above the in vitro IC90 values for anti-HIV activity.

The absolute bioavailability of emtricitabine from Emtriva 200 mg hard capsules was estimated to be 93% and the absolute bioavailability from Emtriva 10 mg/ml oral solution was estimated to be 75%.

In a pilot study in children and a definitive bioequivalence study in adults, the Emtriva 10 mg/ml oral solution was shown to have approximately 80% of the bioavailability of the Emtriva 200 mg hard capsules. The reason for this difference is unknown. Due to this difference in bioavailability, 240 mg emtricitabine administered as the oral solution should provide similar plasma levels to those observed after administration of one 200 mg emtricitabine hard capsule. Therefore, children who weigh at least 33 kg may take either one 200 mg hard capsule daily or the oral solution up to a maximum dose of 240 mg (24 ml), once daily.

Administration of Emtriva 200 mg hard capsules with a high-fat meal or administration of Emtriva 10 mg/ml oral solution with a low-fat or high-fat meal did not affect systemic exposure (AUC0-∞) of emtricitabine; therefore Emtriva 200 mg hard capsules and Emtriva 10 mg/ml oral solution may be administered with or without food.

Distribution: In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 µg/ml. The mean plasma to blood concentration ratio was approximately 1.0 and the mean semen to plasma concentration ratio was approximately 4.0.

The apparent volume of distribution after intravenous administration of emtricitabine was 1.4±0.3 l/kg, indicating that emtricitabine is widely distributed throughout the body to both
intracellular and extracellular fluid spaces.

**Biotransformation:** There is limited metabolism of emtricitabine. The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulphoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose).

Emtricitabine did not inhibit *in vitro* drug metabolism mediated by the following human CYP450 isoenzymes: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4.

Also, emtricitabine did not inhibit uridine-5'-diphosphoglucuronyl transferase, the enzyme responsible for glucuronidation.

**Elimination:** Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%). Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites. The systemic clearance of emtricitabine averaged 307 ml/min (4.03 ml/min/kg). Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours.

**Linearity/non-linearity:** The pharmacokinetics of emtricitabine are proportional to dose over the dose range of 25-200 mg following single or repeated administration.

**Intracellular pharmacokinetics:** In a clinical study, the intracellular half-life of emtricitabine-triphosphate in peripheral blood mononuclear cells was 39 hours. Intracellular triphosphate levels increased with dose, but reached a plateau at doses of 200 mg or greater.

**Adults with renal insufficiency:** Pharmacokinetic parameters were determined following administration of a single dose of 200 mg emtricitabine hard capsules to 30 non-HIV infected subjects with varying degrees of renal insufficiency. Subjects were grouped according to baseline creatinine clearance (> 80 ml/min as normal function; 50-80 ml/min as mild impairment; 30-49 ml/min as moderate impairment; < 30 ml/min as severe impairment; < 15 ml/min as functionally anephric requiring haemodialysis).

The systemic emtricitabine exposure (mean ± standard deviation) increased from 11.8±2.9 µg·h/ml in subjects with normal renal function to 19.9±1.1, 25.0±5.7 and 34.0±2.1 µg·h/ml, in patients with mild, moderate and severe renal impairment, respectively.

In patients with ESRD on haemodialysis, approximately 30% of the emtricitabine dose was recovered in dialysate over a 3 hour dialysis period which had been started within 1.5 hours of emtricitabine dosing (blood flow rate of 400 ml/min and dialysate flow rate of approximately 600 ml/min).

**Hepatic insufficiency:** The pharmacokinetics of emtricitabine have not been studied in non-HBV infected subjects with varying degrees of hepatic insufficiency. In general, emtricitabine pharmacokinetics in HBV infected subjects were similar to those in healthy subjects and in HIV infected subjects.

**Age, gender and ethnicity:** In general, the pharmacokinetics of emtricitabine in infants, children and adolescents (aged 4 months up to 18 years) are similar to those seen in adults.

The mean AUC in 77 infants, children and adolescents receiving 6 mg/kg emtricitabine once daily as oral solution or 200 mg emtricitabine as hard capsules once daily was similar to the mean AUC of 10.0 µg·h/ml in 20 adults receiving 200 mg hard capsules once daily.

In an open-label, non-comparative study, pharmacokinetic data were obtained from 20 neonates of HIV infected mothers who received two 4-day courses of emtricitabine oral solution between the first week of life and 3 months of age at a dose level of 3 mg/kg once daily. This dose is half of that approved for infants aged 4 months and over (6 mg/kg). The apparent total body clearance at steady
state (CL/F) increased with age over the 3-month period with a corresponding decrease in AUC. Plasma emtricitabine exposure (AUC) in infants up to 3 months of age who received 3 mg/kg emtricitabine once daily was similar to that observed using 6 mg/kg daily doses in HIV infected adults and children aged 4 months and over.

Pharmacokinetic data are not available in the elderly.

Although the mean $C_{\text{max}}$ and $C_{\text{min}}$ were approximately 20% higher and mean AUC was 16% higher in females compared to males, this difference was not considered clinically significant. No clinically important pharmacokinetic difference due to race has been identified.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and reproductive/developmental toxicity. Emtricitabine did not show any carcinogenic potential in long-term oral carcinogenicity studies in mice and rats.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

*Capsule contents:*
Cellulose, microcrystalline (E460)
Crospovidone
Magnesium stearate (E572)
Povidone (E1201)

*Capsule shell:*
Gelatin
Indigotine (E132)
Titanium dioxide (E171)

*Printing ink containing:*
Black iron oxide (E172)
Shellac (E904)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

White high-density polyethylene (HDPE) bottle fitted with a child-resistant closure, containing 30 hard capsules.

Blisters made of polychlorotrifluorethylene (PCTFE) / polyethylene (PE) / polyvinylchloride (PVC) / aluminium. Each blister pack contains 30 hard capsules.
Pack size: 30 hard capsules.

6.6 Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Gilead Sciences International Limited
Cambridge
CB21 6GT
United Kingdom

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/03/261/001
EU/1/03/261/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 24 October 2003
Date of last renewal: 22 September 2008

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu/.
1. NAME OF THE MEDICINAL PRODUCT

Emtriva 10 mg/ml oral solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of Emtriva oral solution contains 10 mg emtricitabine.

Excipient(s):

Each dose (24 ml) contains 36 mg methyl parahydroxybenzoate (E218), 3.6 mg propyl parahydroxybenzoate (E216), 1.2 mg Sunset Yellow (E110) and has a sodium content of 254 mg. For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Oral solution.

The clear solution is orange to dark orange in colour.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Emtriva is indicated for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents.

This indication is based on studies in treatment-naïve patients and treatment-experienced patients with stable virological control. There is no experience of the use of Emtriva in patients who are failing their current regimen or who have failed multiple regimens (see section 5.1).

When deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate.

4.2 Posology and method of administration

Therapy should be initiated by a physician experienced in the management of HIV infection.

Emtriva 10 mg/ml oral solution may be taken with or without food. A measuring cup is provided (see section 6.5).

Adults: The recommended dose of Emtriva 10 mg/ml oral solution is 240 mg (24 ml) once daily.

Infants, children and adolescents up to 18 years of age: The recommended dose of Emtriva 10 mg/ml oral solution is 6 mg/kg up to a maximum of 240 mg (24 ml) once daily.

Children who weigh at least 33 kg may either take one 200 mg hard capsule daily or may take emtricitabine as the oral solution up to a maximum of 240 mg once daily.

There are no data regarding the efficacy and only very limited data regarding the safety of emtricitabine in infants below 4 months of age. Therefore Emtriva is not recommended for use in those aged less than 4 months. (For pharmacokinetic data in this age group, see section 5.2).
Emtriva 200 mg hard capsules are available for adults, adolescents and children who weigh at least 33 kg and can swallow hard capsules. Please refer to the Summary of Product Characteristics for Emtriva 200 mg hard capsules. Due to a difference in the bioavailability of emtricitabine between the hard capsule and oral solution presentations, 240 mg emtricitabine administered as the oral solution (24 ml) should provide similar plasma levels to those observed after administration of one 200 mg emtricitabine hard capsule (see section 5.2).

**Elderly:** There are no safety and efficacy data available in patients over the age of 65 years. However, no adjustment in the recommended daily dose for adults should be required unless there is evidence of renal insufficiency.

**Renal insufficiency:** Emtricitabine is eliminated by renal excretion and exposure to emtricitabine was significantly increased in patients with renal insufficiency (see section 5.2). Dose or dose interval adjustment is required in all patients with creatinine clearance < 50 ml/min (see section 4.4).

Table 1 below provides daily doses of Emtriva 10 mg/ml oral solution according to the degree of renal insufficiency. The safety and efficacy of these doses have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in these patients (see section 4.4).

Patients with renal insufficiency can also be managed by administration of Emtriva 200 mg hard capsules at modified dose intervals. Please refer to the Summary of Product Characteristics for Emtriva 200 mg hard capsules.

**Table 1: Daily doses of Emtriva 10 mg/ml oral solution adjusted according to creatinine clearance**

<table>
<thead>
<tr>
<th>Creatinine Clearance (CLcr) (ml/min)</th>
<th>≥ 50</th>
<th>30-49</th>
<th>15-29</th>
<th>&lt; 15 (functionally anephric, requiring intermittent haemodialysis)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommended dose of Emtriva 10 mg/ml oral solution every 24 hours</td>
<td>240 mg (24 ml)</td>
<td>120 mg (12 ml)</td>
<td>80 mg (8 ml)</td>
<td>60 mg (6 ml)</td>
</tr>
</tbody>
</table>

* Assumes a 3 h haemodialysis session three times a week commencing at least 12 h after administration of the last dose of emtricitabine.

Patients with end-stage renal disease (ESRD) managed with other forms of dialysis such as ambulatory peritoneal dialysis have not been studied and no dose recommendations can be made.

No data are available on which to make a dosage recommendation in paediatric patients with renal insufficiency.

**Hepatic insufficiency:** No data are available on which to make a dose recommendation for patients with hepatic insufficiency. However, based on the minimal metabolism of emtricitabine and the renal route of elimination it is unlikely that a dose adjustment would be required in patients with hepatic insufficiency (see section 5.2).

If Emtriva is discontinued in patients co-infected with HIV and HBV, these patients should be closely
monitored for evidence of exacerbation of hepatitis (see section 4.4).

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients.

4.4 Special warnings and precautions for use

Emtriva should not be taken with any other medicinal products containing emtricitabine or medicinal products containing lamivudine.

General: Emtricitabine is not recommended as monotherapy for the treatment of HIV infection. It must be used in combination with other antiretrovirals. Please also refer to the Summaries of Product Characteristics of the other antiretroviral medicinal products used in the combination regimen.

Patients receiving emtricitabine or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.

Patients should be advised that antiretroviral therapies, including emtricitabine, have not been proven to prevent the risk of transmission of HIV to others through sexual contact or blood contamination. Appropriate precautions should continue to be used. Patients should also be informed that emtricitabine is not a cure for HIV infection.

Renal function: Emtricitabine is principally eliminated by the kidney via glomerular filtration and active tubular secretion. Emtricitabine exposure may be markedly increased in patients with moderate or severe renal insufficiency (creatinine clearance < 50 ml/min) receiving daily doses of 200 mg emtricitabine as hard capsules or 240 mg as the oral solution. Consequently, either a dose interval adjustment (using Emtriva 200 mg hard capsules) or a reduction in the daily dose of emtricitabine (using Emtriva 10 mg/ml oral solution) is required in all patients with creatinine clearance < 50 ml/min. The safety and efficacy of the reduced doses provided in section 4.2 are based on single dose pharmacokinetic data and modelling and have not been clinically evaluated. Therefore, clinical response to treatment and renal function should be closely monitored in patients treated with a reduced dose of emtricitabine (see sections 4.2 and 5.2).

Caution should be exercised when emtricitabine is co-administered with medicinal products that are eliminated by active tubular secretion as such co-administration may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product, due to competition for this elimination pathway (see section 4.5).

Lactic acidosis: Lactic acidosis, usually associated with hepatic steatosis, has been reported with the use of nucleoside analogues. Early symptoms (symptomatic hyperlactataemia) include benign digestive symptoms (nausea, vomiting and abdominal pain), non-specific malaise, loss of appetite, weight loss, respiratory symptoms (rapid and/or deep breathing) or neurological symptoms (including motor weakness). Lactic acidosis has a high mortality and may be associated with pancreatitis, liver failure or renal failure. Lactic acidosis generally occurred after a few or several months of treatment.

Treatment with nucleoside analogues should be discontinued in the setting of symptomatic hyperlactataemia and metabolic/lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.

Caution should be exercised when administering nucleoside analogues to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease and hepatic steatosis (including certain medicinal products and alcohol). Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk.
Patients at increased risk should be followed closely.

**Lipodystrophy:** Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV patients. The long-term consequences of these events are currently unknown. Knowledge about the mechanism is incomplete. A connection between visceral lipomatosis and protease inhibitors, and lipoatrophy and nucleoside reverse transcriptase inhibitors has been hypothesised. A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances. Clinical examination should include evaluation for physical signs of fat redistribution. Consideration should be given to the measurement of fasting serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate.

**Liver function:** Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. Patients with chronic hepatitis B or C infection treated with combination antiretroviral therapy are at increased risk of experiencing severe, and potentially fatal, hepatic adverse events. In case of concomitant antiviral therapy for hepatitis B or C, please also refer to the relevant Summary of Product Characteristics for these medicinal products.

If there is evidence of exacerbations of liver disease in such patients, interruption or discontinuation of treatment must be considered.

**Patients co-infected with hepatitis B virus (HBV):** Emtricitabine is active *in vitro* against HBV. However, limited data are available on the efficacy and safety of emtricitabine (as a 200 mg hard capsule once daily) in patients who are co-infected with HIV and HBV. The use of emtricitabine in patients with chronic HBV induces the same mutation pattern in the YMDD motif observed with lamivudine therapy. The YMDD mutation confers resistance to both emtricitabine and lamivudine.

Patients co-infected with HIV and HBV should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment with emtricitabine for evidence of exacerbations of hepatitis. Such exacerbations have been seen following discontinuation of emtricitabine treatment in HBV infected patients without concomitant HIV infection and have been detected primarily by serum alanine aminotransferase (ALT) elevations in addition to re-emergence of HBV DNA. In some of these patients, HBV reactivation was associated with more severe liver disease, including decompensation and liver failure. There is insufficient evidence to determine whether re-initiation of emtricitabine alters the course of post-treatment exacerbations of hepatitis. In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbations of hepatitis may lead to hepatic decompensation.

**Mitochondrial dysfunction:** Nucleoside and nucleotide analogues have been demonstrated *in vitro* and *in vivo* to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in HIV negative infants exposed *in utero* and/or postnatally to nucleoside analogues. The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlactataemia, hyperlipasaemia). These events are often transitory. Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). Whether the neurological disorders are transient or permanent is currently unknown. Any child exposed *in utero* to nucleoside and nucleotide analogues, even HIV negative children, should have clinical and laboratory follow-up and should be fully investigated for possible mitochondrial dysfunction in case of relevant signs or symptoms. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.

**Immune Reactivation Syndrome:** In HIV infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and *Pneumocystis jirovecii* pneumonia. Any inflammatory symptoms
should be evaluated and treatment instituted when necessary.

_Osteonecrosis:_ Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.

Emtriva oral solution contains Sunset Yellow (E110) which may cause allergic reactions, methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). This medicinal product contains 254 mg of sodium per dose which should be taken into consideration by patients on a controlled sodium diet.

4.5 Interaction with other medicinal products and other forms of interaction

_In vitro_, emtricitabine did not inhibit metabolism mediated by any of the following human CYP450 isoforms: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4. Emtricitabine did not inhibit the enzyme responsible for glucuronidation. Based on the results of these _in vitro_ experiments and the known elimination pathways of emtricitabine, the potential for CYP450 mediated interactions involving emtricitabine with other medicinal products is low.

There are no clinically significant interactions when emtricitabine is co-administered with indinavir, zidovudine, stavudine, famciclovir or tenofovir disoproxil fumarate.

Emtricitabine is primarily excreted via glomerular filtration and active tubular secretion. With the exception of famciclovir and tenofovir disoproxil fumarate, the effect of co-administration of emtricitabine with medicinal products that are excreted by the renal route, or other medicinal products known to affect renal function, has not been evaluated. Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product due to competition for this elimination pathway.

There is no clinical experience as yet on the co-administration of cytidine analogues. Consequently, the use of emtricitabine in combination with lamivudine or zalcitabine for the treatment of HIV infection cannot be recommended at this time.

4.6 Pregnancy and lactation

The safety of emtricitabine in human pregnancy has not been established.

Animal studies do not indicate direct or indirect harmful effects of emtricitabine with respect to pregnancy, foetal development, parturition or postnatal development (see section 5.3).

Emtricitabine should be used during pregnancy only if necessary.

Given that the potential risks to developing human foetuses are unknown, the use of emtricitabine in women of childbearing potential must be accompanied by the use of effective contraception.

It is not known if emtricitabine is excreted in human milk.

It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, patients should be informed that dizziness has been reported during treatment with emtricitabine.
4.8 Undesirable effects

a. Summary of the safety profile

In clinical trials of HIV infected adults, the most frequently occurring adverse reactions to emtricitabine were diarrhoea (14.0%), headache (10.2%), elevated creatine kinase (10.2%) and nausea (10.0%). In addition to the adverse reactions reported in adults, anaemia (9.5%) and skin discoloration (31.8%) occurred more frequently in clinical trials involving HIV infected paediatric patients.

Lactic acidosis, severe hepatomegaly with steatosis and lipodystrophy are associated with emtricitabine (see sections 4.4 and 4.8c).

Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump) (see section 4.4).

Discontinuation of Emtriva therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis (see section 4.4).

b. Tabulated summary of adverse reactions

Assessment of adverse reactions from clinical study data is based on experience in three studies in adults (n=1,479) and three paediatric studies (n=169). In the adult studies, 1,039 treatment-naïve and 440 treatment-experienced patients received emtricitabine (n=814) or comparator medicinal product (n=665) for 48 weeks in combination with other antiretroviral medicinal products.

The adverse reactions with suspected (at least possible) relationship to treatment in adults from clinical trial and post-marketing experience are listed in Table 2 below by body system organ class and frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10) or uncommon (≥ 1/1,000 to < 1/100).

Table 2: Tabulated summary of adverse reactions associated with emtricitabine based on clinical study and post-marketing experience

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Emtricitabine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and lymphatic system disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>neutropenia</td>
</tr>
<tr>
<td>Uncommon:</td>
<td>anaemia</td>
</tr>
<tr>
<td><strong>Immune system disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>allergic reaction</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>hypertriglyceridaemia, hyperglycaemia</td>
</tr>
<tr>
<td><strong>Psychiatric disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>insomnia, abnormal dreams</td>
</tr>
<tr>
<td><strong>Nervous system disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Very common:</td>
<td>headache</td>
</tr>
<tr>
<td>Common:</td>
<td>dizziness</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Very common:</td>
<td>diarrhoea, nausea</td>
</tr>
<tr>
<td>Common:</td>
<td>elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal pain, dyspepsia</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders:</strong></td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>elevated serum aspartate aminotransferase (AST) and/or elevated serum alanine aminotransferase (ALT), hyperbilirubinaemia</td>
</tr>
</tbody>
</table>
Skin and subcutaneous tissue disorders:

Common: vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation)\textsuperscript{1,2}

Uncommon: angioedema\textsuperscript{3}

Musculoskeletal and connective tissue disorders:

Very common: elevated creatine kinase

General disorders and administration site conditions:

Common: asthenia, pain

\textsuperscript{1} See section \textit{c. Description of selected adverse reactions} for more details.

\textsuperscript{2} Anaemia was common and skin discolouration (increased pigmentation) was very common when emtricitabine was administered to paediatric patients (see section d.).

\textsuperscript{3} This adverse reaction, which was identified through post-marketing surveillance, was not observed in randomised controlled clinical trials in adults or paediatric HIV clinical trials of emtricitabine. The frequency category of uncommon was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in these clinical studies (n=1,563).

\textit{c. Description of selected adverse reactions}

\textbf{Skin discolouration (increased pigmentation):} Skin discolouration, manifested by hyperpigmentation mainly on the palms and/or soles, was generally mild, asymptomatic and of little clinical significance. The mechanism is unknown.

Lipids, lipodystrophy and metabolic abnormalities: Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).

Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump) (see section 4.4).

\textit{Immune Reactivation Syndrome}: In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise (see section 4.4).

\textit{Osteonecrosis}: Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). The frequency of this is unknown (see section 4.4).

\textit{Lactic acidosis and severe hepatomegaly with steatosis}: Lactic acidosis, usually associated with hepatic steatosis, has been reported with the use of nucleoside analogues (see section 4.4).

\textit{d. Paediatric population}

Assessment of adverse reactions in paediatric patients from clinical study data is based on experience in three paediatric studies (n=169) where treatment-naïve (n=123) and treatment-experienced (n=46) paediatric HIV infected patients aged 4 months to 18 years were treated with emtricitabine in combination with other antiretroviral agents.

In addition to the adverse reactions reported in adults (see section b.), the following adverse reactions were observed more frequently in paediatric patients: anaemia was common (9.5\%) and skin discolouration (increased pigmentation) was very common (31.8\%) in paediatric patients.

\textit{e. Other special population(s)}

\textit{Elderly}: Emtriva has not been studied in patients over the age of 65. Elderly patients are more likely to have decreased renal function, therefore caution should be exercised when treating elderly patients with Emtriva (see section 4.2).
Patients with renal impairment: Emtricitabine is eliminated by renal excretion and exposure to emtricitabine was significantly increased in patients with renal insufficiency. Dose or dose interval adjustment is required in all patients with creatinine clearance < 50 ml/min (see sections 4.2, 4.4 and 5.2).

HIV/HBV co-infected patients: The adverse reaction profile in patients co-infected with HBV is similar to that observed in patients infected with HIV without co-infection with HBV. However, as would be expected in this patient population, elevations in AST and ALT occurred more frequently than in the general HIV infected population.

Exacerbations of hepatitis after discontinuation of treatment: In HIV infected patients co-infected with HBV, exacerbations of hepatitis may occur after discontinuation of treatment (see section 4.4).

4.9 Overdose

Administration of up to 1,200 mg emtricitabine has been associated with the adverse reactions listed above (see section 4.8).

If overdose occurs, the patient should be monitored for signs of toxicity and standard supportive treatment applied as necessary.

Up to 30% of the emtricitabine dose can be removed by haemodialysis. It is not known whether emtricitabine can be removed by peritoneal dialysis.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Nucleoside and nucleotide reverse transcriptase inhibitors, ATC code: J05AF09.

Mechanism of action: Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to human immunodeficiency virus (HIV-1 and HIV-2) and hepatitis B virus (HBV).

Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competitively inhibits HIV-1 reverse transcriptase, resulting in DNA chain termination. Emtricitabine is a weak inhibitor of mammalian DNA polymerase α, β and ε and mitochondrial DNA polymerase γ.

Emtricitabine did not exhibit cytotoxicity to peripheral blood mononuclear cells (PBMCs), established lymphocyte and monocyte-macrophage cell lines or bone marrow progenitor cells in vitro. There was no evidence of toxicity to mitochondria in vitro or in vivo.

Antiviral activity in vitro: The 50% inhibitory concentration (IC₅₀) value for emtricitabine against laboratory and clinical isolates of HIV-1 was in the range of 0.0013 to 0.5 µmol/l. In combination studies of emtricitabine with protease inhibitors, nucleoside, nucleotide and non-nucleoside analogue inhibitors of HIV reverse transcriptase, additive to synergistic effects were observed. Most of these combinations have not been studied in humans.

When tested for activity against laboratory strains of HBV, the 50% inhibitory concentration (IC₅₀) value for emtricitabine was in the range of 0.01 to 0.04 µmol/l.

Resistance: HIV-1 resistance to emtricitabine develops as the result of changes at codon 184 causing the methionine to be changed to a valine (an isoleucine intermediate has also been observed) of the HIV reverse transcriptase. This HIV-1 mutation was observed in vitro and in HIV-1 infected patients.

Emtricitabine-resistant viruses were cross-resistant to lamivudine, but retained sensitivity to other
nucleoside reverse transcriptase inhibitors (NRTIs) (zidovudine, stavudine, tenofovir, abacavir, didanosine and zalcitabine), all non-nucleoside reverse transcriptase inhibitors (NNRTIs) and all protease inhibitors (PIs). Viruses resistant to zidovudine, zalcitabine, didanosine and NNRTIs retained their sensitivity to emtricitabine (IC_{50}=0.002 µmol/l to 0.08 µmol/l).

**Clinical experience:** Emtricitabine in combination with other antiretroviral agents, including nucleoside analogues, non-nucleoside analogues and protease inhibitors, has been shown to be effective in the treatment of HIV infection in treatment-naïve patients and treatment-experienced patients with stable virological control. There is no experience of the use of emtricitabine in patients who are failing their current regimen or who have failed multiple regimens. There is no clinical experience of the use of emtricitabine in infants less than 4 months of age.

In antiretroviral treatment-naïve adults, emtricitabine was significantly superior to stavudine when both medicinal products were taken in combination with didanosine and efavirenz through 48 weeks of treatment. Phenotypic analysis showed no significant changes in emtricitabine susceptibility unless the M184V/I mutation had developed.

In virologically stable treatment-experienced adults, emtricitabine, in combination with an NRTI (either stavudine or zidovudine) and a protease inhibitor (PI) or an NNRTI was shown to be non-inferior to lamivudine with respect to the proportion of responders (< 400 copies/ml) through 48 weeks (77% emtricitabine, 82% lamivudine). Additionally, in a second study, treatment-experienced adults on a stable PI based highly active antiretroviral therapy (HAART) regimen were randomised to a once daily regimen containing emtricitabine or to continue with their PI-HAART regimen. At 48 weeks of treatment the emtricitabine-containing regimen demonstrated an equivalent proportion of patients with HIV RNA < 400 copies/ml (94% emtricitabine versus 92%) and a greater proportion of patients with HIV RNA < 50 copies/ml (95% emtricitabine versus 87%) compared with the patients continuing with their PI-HAART regimen.

In infants and children older than 4 months, the majority of patients achieved or maintained complete suppression of plasma HIV-1 RNA through 48 weeks (89% achieved ≤ 400 copies/ml and 77% achieved ≤ 50 copies/ml).

### 5.2 Pharmacokinetic properties

**Absorption:** Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose. In 20 HIV infected subjects receiving 200 mg emtricitabine daily as hard capsules, steady-state plasma emtricitabine peak concentrations (C_{max}), trough concentrations (C_{min}) and area under the plasma concentration time curve over a 24-hour dosing interval (AUC) were 1.8±0.7 µg/ml, 0.09±0.07 µg/ml and 10.0±3.1 µg·h/ml, respectively. Steady-state trough plasma concentrations reached levels approximately 4-fold above the *in vitro* IC_{90} values for anti-HIV activity.

The absolute bioavailability of emtricitabine from Emtriva 200 mg hard capsules was estimated to be 93% and the absolute bioavailability from Emtriva 10 mg/ml oral solution was estimated to be 75%.

In a pilot study in children and a definitive bioequivalence study in adults, the Emtriva 10 mg/ml oral solution was shown to have approximately 80% of the bioavailability of the Emtriva 200 mg hard capsules. The reason for this difference is unknown. Due to this difference in bioavailability, 240 mg emtricitabine administered as the oral solution should provide similar plasma levels to those observed after administration of one 200 mg emtricitabine hard capsule. Therefore, children who weigh at least 33 kg may take either one 200 mg hard capsule daily or the oral solution up to a maximum dose of 240 mg (24 ml), once daily.

Administration of Emtriva 200 mg hard capsules with a high-fat meal or administration of Emtriva 10 mg/ml oral solution with a low-fat or high-fat meal did not affect systemic exposure (AUC_{0-∞}) of emtricitabine; therefore Emtriva 200 mg hard capsules and Emtriva 10 mg/ml oral solution may be administered with or without food.
**Distribution:** *In vitro* binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 µg/ml. The mean plasma to blood concentration ratio was approximately 1.0 and the mean semen to plasma concentration ratio was approximately 4.0.

The apparent volume of distribution after intravenous administration of emtricitabine was 1.4±0.3 l/kg, indicating that emtricitabine is widely distributed throughout the body to both intracellular and extracellular fluid spaces.

**Biotransformation:** There is limited metabolism of emtricitabine. The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulphoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose).

Emtricitabine did not inhibit *in vitro* drug metabolism mediated by the following human CYP450 isoenzymes: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4.

Also, emtricitabine did not inhibit uridine-5'-diphosphoglucuronyl transferase, the enzyme responsible for glucuronidation.

**Elimination:** Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%). Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites. The systemic clearance of emtricitabine averaged 307 ml/min (4.03 ml/min/kg). Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours.

**Linearity/non-linearity:** The pharmacokinetics of emtricitabine are proportional to dose over the dose range of 25-200 mg following single or repeated administration.

**Intracellular pharmacokinetics:** In a clinical study, the intracellular half-life of emtricitabine-triphosphate in peripheral blood mononuclear cells was 39 hours. Intracellular triphosphate levels increased with dose, but reached a plateau at doses of 200 mg or greater.

**Adults with renal insufficiency:** Pharmacokinetic parameters were determined following administration of a single dose of 200 mg emtricitabine hard capsules to 30 non-HIV infected subjects with varying degrees of renal insufficiency. Subjects were grouped according to baseline creatinine clearance (> 80 ml/min as normal function; 50-80 ml/min as mild impairment; 30-49 ml/min as moderate impairment; < 30 ml/min as severe impairment; < 15 ml/min as functionally anephric requiring haemodialysis).

The systemic emtricitabine exposure (mean ± standard deviation) increased from 11.8±2.9 µg·h/ml in subjects with normal renal function to 19.9±1.1, 25.0±5.7 and 34.0±2.1 µg·h/ml, in patients with mild, moderate and severe renal impairment, respectively.

In patients with ESRD on haemodialysis, approximately 30% of the emtricitabine dose was recovered in dialysate over a 3 hour dialysis period which had been started within 1.5 hours of emtricitabine dosing (blood flow rate of 400 ml/min and dialysate flow rate of approximately 600 ml/min).

**Hepatic insufficiency:** The pharmacokinetics of emtricitabine have not been studied in non-HBV infected subjects with varying degrees of hepatic insufficiency. In general, emtricitabine pharmacokinetics in HBV infected subjects were similar to those in healthy subjects and in HIV infected subjects.

**Age, gender and ethnicity:** In general, the pharmacokinetics of emtricitabine in infants, children and adolescents (aged 4 months up to 18 years) are similar to those seen in adults.

The mean AUC in 77 infants, children and adolescents receiving 6 mg/kg emtricitabine once daily as
oral solution or 200 mg emtricitabine as hard capsules once daily was similar to the mean AUC of 10.0 µg·h/ml in 20 adults receiving 200 mg hard capsules once daily.

In an open-label, non-comparative study, pharmacokinetic data were obtained from 20 neonates of HIV infected mothers who received two 4-day courses of emtricitabine oral solution between the first week of life and 3 months of age at a dose level of 3 mg/kg once daily. This dose is half of that approved for infants aged 4 months and over (6 mg/kg). The apparent total body clearance at steady state (CL/F) increased with age over the 3-month period with a corresponding decrease in AUC. Plasma emtricitabine exposure (AUC) in infants up to 3 months of age who received 3 mg/kg emtricitabine once daily was similar to that observed using 6 mg/kg daily doses in HIV infected adults and children aged 4 months and over.

Pharmacokinetic data are not available in the elderly.

Although the mean $C_{\text{max}}$ and $C_{\text{min}}$ were approximately 20% higher and mean AUC was 16% higher in females compared to males, this difference was not considered clinically significant. No clinically important pharmacokinetic difference due to race has been identified.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and reproductive/developmental toxicity. Emtricitabine did not show any carcinogenic potential in long-term oral carcinogenicity studies in mice and rats.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Cotton candy flavouring
Disodium edetate
Hydrochloric acid
Methyl parahydroxybenzoate (E218)
Propylene glycol
Propyl parahydroxybenzoate (E216)
Sodium hydroxide
Sodium phosphate monobasic hydrate
Sunset yellow (E110)
Purified water
Xylitol (E967)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

After first opening: 45 days.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C).

After opening: Do not store above 25°C.
6.5 Nature and contents of container

Amber-coloured polyethylene terephthalate (PET) bottle with a child-resistant closure. The pack also contains a 30 ml polypropylene measuring cup with 1.0 ml graduations. The bottle contains 170 ml of solution.

6.6 Special precautions for disposal

Patients should be instructed that any solution left in the bottle 45 days after opening should be discarded according to local requirements or returned to the pharmacy.

7. MARKETING AUTHORISATION HOLDER

Gilead Sciences International Limited
Cambridge
CB21 6GT
United Kingdom

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/03/261/003

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 24 October 2003
Date of last renewal: 22 September 2008

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu/.
ANNEX II

A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OF THE MARKETING AUTHORISATION
A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Gilead Sciences Limited
Unit 13 Stillorgan Industrial Park
Blackrock County Dublin
Ireland

Gilead Sciences Limited
IDA Business & Technology Park
Carrigtohill Co. Cork
Ireland

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OF THE MARKETING AUTHORISATION

• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Not applicable.

• OTHER CONDITIONS

The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.

Pharmacovigilance system

The MAH must ensure that the system of pharmacovigilance, as described in version 6.0 presented in Module 1.8.1 of the Marketing Authorisation, is in place and functioning before and whilst the product is on the market.

Risk Management Plan

As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).

In addition, an updated RMP should be submitted

• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities
• Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
• At the request of the European Medicines Agency
PSURs:

The Marketing Authorisation Holder will submit PSUR’s on an annual basis.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
| PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING |
| BOTTLE AND CARTON LABELLING |

1. **NAME OF THE MEDICINAL PRODUCT**

Emtriva 200 mg hard capsules  
Emtricitabine

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each hard capsule contains 200 mg emtricitabine.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

30 hard capsules.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.  
Read the package leaflet before use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

Keep out of the reach and sight of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**
<table>
<thead>
<tr>
<th><strong>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilead Sciences Intl Ltd</td>
<td></td>
</tr>
<tr>
<td>Cambridge</td>
<td></td>
</tr>
<tr>
<td>CB21 6GT</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>12. MARKETING AUTHORISATION NUMBER(S)</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/03/261/001</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>13. BATCH NUMBER</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>14. GENERAL CLASSIFICATION FOR SUPPLY</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicinal product subject to medical prescription.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>15. INSTRUCTIONS ON USE</strong></th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>16. INFORMATION IN BRAILLE</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Emtriva [outer packaging only]</td>
<td></td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING

BLISTER CARTON LABELLING

1. NAME OF THE MEDICINAL PRODUCT

Emtriva 200 mg hard capsules
Emtricitabine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each hard capsule contains 200 mg emtricitabine.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

30 hard capsules.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use.
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Gilead Sciences Intl Ltd  
Cambridge  
CB21 6GT  
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/03/261/002

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Emtriva [outer packaging only]
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER

1. NAME OF THE MEDICINAL PRODUCT

Emtriva 200 mg hard capsules
Emtricitabine

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Gilead Sciences Intl Ltd

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. OTHER
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING

BOTTLE AND CARTON LABELLING

1. NAME OF THE MEDICINAL PRODUCT

Emtriva 10 mg/ml oral solution
Emtricitabine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each ml contains 10 mg emtricitabine.

3. LIST OF EXCIPIENTS

Contains E110, E216, E218, and sodium. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

170 ml oral solution.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use.

Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

After opening: the solution should be used within 45 days. It is advised to write the date of removal from the refrigerator on the package.

Opened:
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

After opening: do not store above 25°C.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Gilead Sciences Intl Ltd
Cambridge
CB21 6GT
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/03/261/003

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Emtriva [outer packaging only]
B. PACKAGE LEAFLET
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:
1. What Emtriva is and what it is used for
2. Before you take Emtriva
3. How to take Emtriva
4. Possible side effects
5. How to store Emtriva
6. Further information

1. WHAT EMTRIVA IS AND WHAT IT IS USED FOR

Emtriva is a treatment for Human Immunodeficiency Virus (HIV) infection in adults, children and infants above 4 months of age. Emtriva 200 mg hard capsules are only suitable for patients who weigh at least 33 kg. Emtriva oral solution is available for people who have difficulty in swallowing Emtriva hard capsules.

Emtriva contains the active substance emtricitabine. This active substance is an antiretroviral medicine which is used to treat HIV infection. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) which works by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the HIV virus to reproduce itself. Emtriva may lower the amount of HIV in the blood (viral load). It may also help to increase the number of T cells called CD4 cells. Emtriva should always be combined with other medicines to treat HIV infection.

You can still pass on HIV to others while you’re taking this drug, so it is important to take precautions to avoid infecting other people.

This medicine is not a cure for HIV infection. While taking Emtriva you may still develop infections or other illnesses associated with HIV infection.

2. BEFORE YOU TAKE EMTRIVA

Do not take Emtriva

- If you are allergic (hypersensitive) to emtricitabine or any of the other ingredients of Emtriva 200 mg hard capsules listed at the end of this leaflet.

If this applies to you, tell your doctor immediately.

Take special care with Emtriva

- Tell your doctor if you have had kidney disease, or if tests have shown problems with your kidneys. Before starting treatment, your doctor may order blood tests to assess kidney function.
and may advise you to take the capsules less often or prescribe Emtriva oral solution. Your doctor may also order blood tests during treatment to monitor your kidneys.

- **Talk to your doctor if you are over 65.** Emtriva has not been studied in patients over 65 years of age. If you are older than this and are prescribed Emtriva, your doctor will monitor you carefully.

- **Do not give Emtriva to infants** under 4 months of age.

- **Talk to your doctor if you have a history of liver disease, including hepatitis.** Patients with liver disease including chronic hepatitis B or C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. If you have hepatitis B infection, your doctor will carefully consider the best treatment regimen for you. If you have a history of liver disease or chronic hepatitis B infection your doctor may conduct blood tests in order to carefully monitor liver function.

- **If you are diabetic, overweight or have high cholesterol, talk to your doctor.** Combination antiretroviral therapies may raise blood sugar, increase blood fats (hyperlipaemia), cause changes to body fat, and resistance to insulin (see section 4, Possible side effects).

- **Once you start taking Emtriva, look out for possible signs of lactic acidosis.** Medicines containing nucleoside analogues, including Emtriva, can cause lactic acidosis (excess of lactic acid in your blood), together with an enlarged liver. This is a rare but serious side effect; it has occasionally been fatal. Lactic acidosis occurs more often in women, particularly if they are very overweight. If you have liver disease you may also be more at risk of getting this condition. While you are being treated with Emtriva, your doctor will monitor you closely for any signs that you may be developing lactic acidosis. Signs are:
  - Deep, rapid breathing
  - Drowsiness
  - Nausea (feeling sick), vomiting and stomach pain
If you notice any of these symptoms, **tell your doctor immediately.**

- **Look out for infections.** If you have advanced HIV disease (AIDS) and another infection, you may develop inflammation or worsening of the symptoms of infection when you start treatment with Emtriva. These may be signs that your body’s improved immune system is fighting infection. If you notice signs of inflammation or infection soon after you start taking Emtriva, **tell your doctor at once.**

- **Bone problems.** Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms please inform your doctor.

**Taking other medicines**

**You should not take Emtriva** if you are already taking other medicines that contain emtricitabine, lamivudine or zalcitabine, which are also used to treat HIV infection, unless otherwise directed by your doctor.

**Please tell your doctor or pharmacist** if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. They will advise if Emtriva can be taken with your other medicines.

**Do not stop your treatment without contacting your doctor.**
Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine.

- **You must not take Emtriva during pregnancy** unless specifically directed by your doctor. There are no clinical data on the use of Emtriva in pregnant women and it is not usually used unless absolutely necessary.

- **If you could get pregnant** during treatment with Emtriva, you must use an effective method of contraception to stop you getting pregnant.

- **If you become pregnant, or plan to become pregnant**, ask your doctor about the potential benefits and risks of your antiretroviral therapy to you and your child.

If you have taken Emtriva during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.

- **Do not breast-feed if you are taking Emtriva.** It is not yet known whether the active substance in this medicine passes into human breast milk. It is known that the virus can be passed to the baby in breast milk.

Driving and using machines

Emtriva may cause dizziness. If you experience dizziness while taking Emtriva, **do not drive** and do not use any tools or machines.

3. HOW TO TAKE EMTRIVA

- **Always take Emtriva exactly as your doctor has told you.** You should check with your doctor or pharmacist if you are not sure.

**The usual dose:**

- **Adults:** one 200 mg hard capsule each day with or without food. Swallow the hard capsule with a glass of water.

- **Children and adolescents up to 18 years of age** who weigh at least 33 kg and who are able to swallow hard capsules: one 200 mg hard capsule, each day with or without food.

For infants from 4 months, children, and patients who are unable to swallow hard capsules and patients with kidney problems, Emtriva is available as a liquid (an oral solution). If you have difficulty in swallowing the capsules, tell your doctor.

- **Always take the dose recommended by your doctor.** This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.

- **If you have problems with your kidneys,** your doctor may advise you to take Emtriva less frequently.

- **Your doctor will prescribe Emtriva with other antiretroviral medicines.** Please refer to the patient information leaflets of the other antiretrovirals for guidance on how to take those medicines.
If you take more Emtriva than you should

If you accidentally take too many Emtriva hard capsules, contact your doctor or nearest emergency department for advice. Keep the carton with you so that you can easily describe what you have taken.

If you forget to take Emtriva

It is important not to miss a dose of Emtriva.

If you do miss a dose of Emtriva, take it as soon as you can, and then take your next dose at its regular time.

If it is almost time for your next dose anyway, forget about the missed dose. Wait and take the next dose at the regular time. Do not take a double dose to make up for a forgotten hard capsule.

If you are sick (vomit)
If it’s less than an hour since you took Emtriva, take another capsule. You do not need to take another capsule if you were sick more than an hour after taking Emtriva.

If you stop taking Emtriva

- Don’t stop taking Emtriva without talking to your doctor. Stopping treatment with Emtriva may reduce the effectiveness of the anti-HIV therapy recommended by your doctor. Speak with your doctor before you stop, particularly if you are experiencing any side effects or you have another illness. Contact your doctor again before you restart taking Emtriva capsules.

- If you have both HIV infection and hepatitis B, it is especially important not to stop your Emtriva treatment without talking to your doctor first. Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping Emtriva. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of hepatitis.

Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Emtriva can cause side effects, although not everybody gets them.

Tell your doctor about any of the following side effects:

Very common side effects
(These can affect more than 1 user in 10)

- headache, diarrhoea, feeling sick (nausea)

- muscle pain and weakness (if creatine kinase levels in the blood are increased)

Common side effects
(These can affect 1 to 10 users in 100)

- dizziness, weakness, difficulty sleeping, abnormal dreams
• being sick (vomiting), problems with digestion resulting in discomfort after meals, stomach pain
• rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches
• pain

Tests may also show:
• low white blood cell count (a reduced white blood cell count can make you more prone to infection)
• increased triglycerides (fatty acids), bile or sugar in the blood
• liver and pancreas problems

Uncommon side effects
(These can affect 1 to 10 users in 1,000)
• anaemia (low red blood cell count)
• swelling of the face, lips, tongue or throat

Children given emtricitabine experienced changes in skin colour including darkening of the skin in patches (very common) and anaemia (common). Anaemia means the production of red blood cells is reduced, and a child may have symptoms of tiredness or breathlessness.

Medicines like Emtriva can cause lactic acidosis (excess lactic acid in the blood). The following may be signs of lactic acidosis:
• Deep, rapid breathing
• Drowsiness
• Nausea (feeling sick), vomiting and stomach pain
If you notice any of these symptoms, tell your doctor immediately.

Combination antiretroviral therapy (including Emtriva) may change your body shape, by changing the way body fat is distributed. You may lose fat from your legs, arms and face; gain fat around the abdomen (tummy) and internal organs; get larger breasts or fatty lumps on the back of the neck ('buffalo hump'). The cause and the long-term effects of these changes are not yet known.

Combination antiretroviral therapy may also cause hyperlipaemia (increased fats in the blood) and resistance to insulin. Your doctor will test for these changes.

If you get any of the side effects listed, or if you notice any side effects not listed in this leaflet, tell your doctor.

5. HOW TO STORE EMTRIVA

Keep out of the reach and sight of children.

Do not use Emtriva after the expiry date which is stated on the bottle, blister pack and outer carton after \{EXP\}. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. FURTHER INFORMATION

What Emtriva contains

- The active substance is emtricitabine. Each hard capsule contains 200 mg emtricitabine.
- The other ingredients are:
  
  Capsule contents: microcrystalline cellulose (E460), crospovidone, magnesium stearate (E572), povidone (E1201)

  Capsule shell: gelatin, indigotine (E132), titanium dioxide (E171)

  Printing ink containing: black iron oxide (E172), shellac (E904)

What Emtriva looks like and contents of the pack

Emtriva hard capsules have a white opaque body with a light blue opaque cap. Each capsule is printed with “200 mg” on the cap and “GILEAD” and [Gilead logo] on the body in black ink. Emtriva comes in bottles or blister packs containing 30 capsules.

Emtriva is also available as an oral solution for use in children and infants older than 4 months, patients who have difficulty in swallowing and patients with kidney problems. There is a separate Package Leaflet for Emtriva 10 mg/ml oral solution.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:
Gilead Sciences International Limited
Cambridge
CB21 6GT
United Kingdom

Manufacturer:
Gilead Sciences Limited
Unit 13, Stillorgan Industrial Park
Blackrock
County Dublin
Ireland

or

Gilead Sciences Limited
IDA Business & Technology Park
Carraigtohill Co. Cork
Ireland

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien
Gilead Sciences Belgium BVBA
Tél/Tel: + 32 (0) 24 01 35 79

България
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Česká republika
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Danmark
Gilead Sciences Sweden AB
Tlf: + 46 (0) 8 5057 1849

Deutschland
Gilead Sciences GmbH
Tel: + 49 (0) 89 899890-0

Eesti
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Ελλάδα
Gilead Sciences Ελλάς M.EΠΕ.
Τηλ.: + 30 210 8930 100

España
Gilead Sciences, S.L.
Tel: + 34 91 378 98 30

France
Gilead Sciences
Tél: + 33 (0) 1 42 73 70 70

Ireland
Gilead Sciences Ltd
Tel: + 44 (0) 1223 897555

Ísland
Gilead Sciences Sweden AB
Sími: + 46 (0) 8 5057 1849

Italia
Gilead Sciences S.r.l.
Tel: + 39 02 439201

Κύπρος
Gilead Sciences Ελλάς M.EΠΕ.
Τηλ.: + 30 210 8930 100

Latvija
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Luxembourg/Luxemburg
Gilead Sciences Belgium BVBA
Tél/Tel: + 32 (0) 24 01 35 79

Magyarország
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Malta
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Nederland
Gilead Sciences Netherlands B.V.
Tel: + 31 (0) 20 718 3698

Norge
Gilead Sciences Sweden AB
Tlf: + 46 (0) 8 5057 1849

Österreich
Gilead Sciences GesmbH
Tel: + 43 1 260 830

Polska
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Portugal
Gilead Sciences, Lda.
Tel: + 351 21 7928790

România
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Slovenija
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Slovenská republika
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Suomi/Finland
Gilead Sciences Sweden AB
Puh/Tel: + 46 (0) 8 5057 1849

Sverige
Gilead Sciences Sweden AB
Tel: + 46 (0) 8 5057 1849

United Kingdom
Gilead Sciences Ltd
Tel: + 44 (0) 1223 897555
This leaflet was last approved in

Detailed information on this medicine is available on the European Medicines Agency (EMA) website: http://www.ema.europa.eu/.
Emtriva is a treatment for Human Immunodeficiency Virus (HIV) infection in adults, children and infants above 4 months of age. Emtriva oral solution is particularly suitable for people who have difficulty in swallowing Emtriva hard capsules.

Emtriva contains the active substance emtricitabine. This active substance is an antiretroviral medicine which is used to treat HIV infection. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) which works by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the HIV virus to reproduce itself. Emtriva may lower the amount of HIV in the blood (viral load). It may also help to increase the number of T cells called CD4 cells. Emtriva should always be combined with other medicines to treat HIV infection.

You can still pass on HIV to others while you’re taking this drug, so it is important to take precautions to avoid infecting other people.

This medicine is not a cure for HIV infection. While taking Emtriva you may still develop infections or other illnesses associated with HIV infection.

2. BEFORE YOU TAKE EMTRIVA

Do not take Emtriva

- If you are allergic (hypersensitive) to emtricitabine or any of the other ingredients of Emtriva 10 mg/ml oral solution listed at the end of this leaflet.

  If this applies to you, tell your doctor immediately.

Take special care with Emtriva

- Tell your doctor if you have had kidney disease, or if tests have shown problems with your kidneys. Before starting treatment, your doctor may order blood tests to assess kidney function
and may advise you to take a reduced dose of the oral solution or prescribe Emtriva hard capsules. Your doctor may also order blood tests during treatment to monitor your kidneys.

- **Talk to your doctor if you are over 65.** Emtriva has not been studied in patients over 65 years of age. If you are older than this and are prescribed Emtriva, your doctor will monitor you carefully.

- **Do not give Emtriva to infants** under 4 months of age.

- **Talk to your doctor if you have a history of liver disease, including hepatitis.** Patients with liver disease including chronic hepatitis B or C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. If you have hepatitis B infection, your doctor will carefully consider the best treatment regimen for you. If you have a history of liver disease or chronic hepatitis B infection your doctor may conduct blood tests in order to carefully monitor liver function.

- **If you are diabetic, overweight or have high cholesterol, talk to your doctor.** Combination antiretroviral therapies may raise blood sugar, increase blood fats (hyperlipaemia), cause changes to body fat, and resistance to insulin (see section 4, Possible side effects).

- **Once you start taking Emtriva, look out for possible signs of lactic acidosis.** Medicines containing nucleoside analogues, including Emtriva, can cause lactic acidosis (excess of lactic acid in your blood), together with an enlarged liver. This is a rare but serious side effect; it has occasionally been fatal. Lactic acidosis occurs more often in women, particularly if they are very overweight. If you have liver disease you may also be more at risk of getting this condition. While you are being treated with Emtriva, your doctor will monitor you closely for any signs that you may be developing lactic acidosis. Signs are:
  - Deep, rapid breathing
  - Drowsiness
  - Nausea (feeling sick), vomiting and stomach pain
  If you notice any of these symptoms, **tell your doctor immediately.**

- **Look out for infections.** If you have advanced HIV disease (AIDS) and another infection, you may develop inflammation or worsening of the symptoms of infection when you start treatment with Emtriva. These may be signs that your body’s improved immune system is fighting infection. If you notice signs of inflammation or infection soon after you start taking Emtriva, **tell your doctor at once.**

- **Bone problems.** Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms please inform your doctor.

**Taking other medicines**

**You should not take Emtriva** if you are already taking other medicines that contain emtricitabine, lamivudine or zalcitabine, which are also used to treat HIV infection, unless otherwise directed by your doctor.

**Please tell your doctor or pharmacist** if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. They will advise if Emtriva can be taken with your other medicines.

**Do not stop your treatment without contacting your doctor.**
Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine.

- **You must not take Emtriva during pregnancy** unless specifically directed by your doctor. There are no clinical data on the use of Emtriva in pregnant women and it is not usually used unless absolutely necessary.

- **If you could get pregnant** during treatment with Emtriva, you must use an effective method of contraception to stop you getting pregnant.

- **If you become pregnant, or plan to become pregnant**, ask your doctor about the potential benefits and risks of your antiretroviral therapy to you and your child.

If you have taken Emtriva during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.

- **Do not breast-feed if you are taking Emtriva.** It is not yet known whether the active substance in this medicine passes into human breast milk. It is known that the virus can be passed to the baby in breast milk.

Driving and using machines

Emtriva may cause dizziness. If you experience dizziness while taking Emtriva, **do not drive** and do not use any tools or machines.

Important information about some of the ingredients of Emtriva oral solution

Sunset yellow (E110) may cause allergic reactions. The methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) may cause allergic reactions (possibly delayed). This medicine contains 254 mg of sodium per dose which should be taken into consideration by patients on a controlled sodium diet.

3. **HOW TO TAKE EMTRIVA**

- **Always take Emtriva exactly as your doctor has told you.** You should check with your doctor or pharmacist if you are not sure.

The usual dose:

- **Adults:** Your doctor will advise the correct amount of Emtriva oral solution to be taken. Emtriva oral solution can be taken with or without food.

- **Infants, children and adolescents weighing 40 kg or less:** the dose of Emtriva 10 mg/ml oral solution is calculated according to your body weight. Examples of body weight and the corresponding doses and volumes of the oral solution to be taken each day are given in the table below:
<table>
<thead>
<tr>
<th>Body weight (kg)</th>
<th>Emtricitabine dose (mg)</th>
<th>How much 10 mg/ml solution to take (ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 kg</td>
<td>30 mg</td>
<td>3 ml</td>
</tr>
<tr>
<td>10 kg</td>
<td>60 mg</td>
<td>6 ml</td>
</tr>
<tr>
<td>15 kg</td>
<td>90 mg</td>
<td>9 ml</td>
</tr>
<tr>
<td>20 kg</td>
<td>120 mg</td>
<td>12 ml</td>
</tr>
<tr>
<td>25 kg</td>
<td>150 mg</td>
<td>15 ml</td>
</tr>
<tr>
<td>30 kg</td>
<td>180 mg</td>
<td>18 ml</td>
</tr>
<tr>
<td>35 kg</td>
<td>210 mg</td>
<td>21 ml</td>
</tr>
<tr>
<td>40 kg</td>
<td>240 mg</td>
<td>24 ml</td>
</tr>
</tbody>
</table>

Make sure that you understand how to measure and give the right amount of oral solution according to the weight of the person being treated. Use the measuring cup provided in the carton to measure the correct dose. The cup has lines to indicate each ml of solution.

If you are unsure how much Emtriva you should take ask your doctor or pharmacist.

- **Always take the dose recommended by your doctor.** This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.

- **If you have problems with your kidneys,** your doctor may advise you to take Emtriva less frequently.

- **Your doctor will prescribe Emtriva with other antiretroviral medicines.** Please refer to the patient information leaflets of the other antiretrovirals for guidance on how to take those medicines.

Emtriva is also available as hard capsules. These are only suitable for patients who weigh at least 33 kg and can swallow hard capsules. The blood levels obtained after taking one Emtriva 200 mg hard capsule are similar to those obtained after taking 24 ml of the oral solution. If you would like to switch from taking Emtriva oral solution to Emtriva hard capsules, please talk to your doctor.

**If you take more Emtriva than you should**

If you accidentally take too much Emtriva oral solution, contact your doctor or nearest emergency department for advice. Keep the oral solution bottle with you so that you can easily describe what you have taken.

**If you forget to take Emtriva**

It is important not to miss a dose of Emtriva.

**If you do miss a dose** of Emtriva, take it as soon as you can, and then take your next dose at its regular time.

**If it is almost time for your next dose** anyway, forget about the missed dose. Wait and take the next dose at the regular time. Do not take a double dose to make up for a forgotten dose.
If you are sick (vomit)
If it’s less than an hour since you took Emtriva, take another dose. You do not need to take another dose if you were sick more than an hour after taking Emtriva.

If you stop taking Emtriva

- **Don’t stop taking Emtriva without talking to your doctor.** Stopping treatment with Emtriva may reduce the effectiveness of the anti-HIV therapy recommended by your doctor. Speak with your doctor before you stop, particularly if you are experiencing any side effects or you have another illness. Contact your doctor again before you restart taking Emtriva oral solution.

- **If you have both HIV infection and hepatitis B,** it is especially important not to stop your Emtriva treatment without talking to your doctor first. Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping Emtriva. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of hepatitis.

  Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. **POSSIBLE SIDE EFFECTS**

Like all medicines, Emtriva can cause side effects, although not everybody gets them.

Tell your doctor about any of the following side effects:

**Very common side effects**
*(These can affect more than 1 user in 10)*

- headache, diarrhoea, feeling sick (nausea)
- muscle pain and weakness (if creatine kinase levels in the blood are increased)

**Common side effects**
*(These can affect 1 to 10 users in 100)*

- dizziness, weakness, difficulty sleeping, abnormal dreams
- being sick (vomiting), problems with digestion resulting in discomfort after meals, stomach pain
- rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches
- pain

*Tests may also show:*

- low white blood cell count (a reduced white blood cell count can make you more prone to infection)
- increased triglycerides (fatty acids), bile or sugar in the blood
• liver and pancreas problems

Uncommon side effects
(These can affect 1 to 10 users in 1,000)
• anaemia (low red blood cell count)
• swelling of the face, lips, tongue or throat

Children given emtricitabine experienced changes in skin colour including darkening of the skin in patches (very common) and anaemia (common). Anaemia means the production of red blood cells is reduced, and a child may have symptoms of tiredness or breathlessness.

Medicines like Emtriva can cause lactic acidosis (excess lactic acid in the blood). The following may be signs of lactic acidosis:
• Deep, rapid breathing
• Drowsiness
• Nausea (feeling sick), vomiting and stomach pain
If you notice any of these symptoms, tell your doctor immediately.

Combination antiretroviral therapy (including Emtriva) may change your body shape, by changing the way body fat is distributed. You may lose fat from your legs, arms and face; gain fat around the abdomen (tummy) and internal organs; get larger breasts or fatty lumps on the back of the neck (‘buffalo hump’). The cause and the long-term effects of these changes are not yet known.

Combination antiretroviral therapy may also cause hyperlipaemia (increased fats in the blood) and resistance to insulin. Your doctor will test for these changes.

If you get any of the side effects listed, or if you notice any side effects not listed in this leaflet, tell your doctor.

5. HOW TO STORE EMTRIVA

Keep out of the reach and sight of children.

Do not use Emtriva after the expiry date which is stated on the bottle and outer carton after {EXP}. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C – 8°C) until opened.

After opening the bottle, do not store above 25°C. The content of the bottle should be used up within 45 days of opening. It is advised to write the date of removal from the refrigerator on the package.

If there is any solution left in the bottle after 45 days, this should be discarded according to local requirements or returned to the pharmacy.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. FURTHER INFORMATION

What Emtriva contains
• The active substance is emtricitabine. One ml of Emtriva oral solution contains 10 mg emtricitabine (10 mg/ml).
- **The other ingredients are:** cotton candy flavouring, disodium edetate, hydrochloric acid, methyl parahydroxybenzoate (E218), propylene glycol, propyl parahydroxybenzoate (E216), sodium hydroxide, sodium phosphate monobasic hydrate, sunset yellow (E110), purified water, xylitol (E967).

**What Emtriva looks like and contents of the pack**

Emtriva oral solution is a clear, orange to dark orange solution that comes in bottles containing 170 ml with a measuring cup.

Emtriva is also available as hard capsules. These are only suitable for patients who weigh at least 33 kg and can swallow hard capsules. There is a separate Package Leaflet for Emtriva 200 mg hard capsules.

**Marketing Authorisation Holder and Manufacturer**

Marketing Authorisation Holder:
Gilead Sciences International Limited
Cambridge
CB21 6GT
United Kingdom

Manufacturer:
Gilead Sciences Limited
Unit 13, Stillorgan Industrial Park
Blackrock
County Dublin
Ireland

or

Gilead Sciences Limited
IDA Business & Technology Park
Carrigtwohill Co. Cork
Ireland

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**Belgïe/Belgique/Belgien**
Gilead Sciences Belgium BVBA
Tél/Tel: + 32 (0) 24 01 35 79

**Luxembourg/Luxemburg**
Gilead Sciences Belgium BVBA
Tél/Tel: + 32 (0) 24 01 35 79

**България**
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

**Magyarország**
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

**Česká republika**
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

**Malta**
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

**Danmark**
Gilead Sciences Sweden AB
Tel: + 46 (0) 8 5057 1849

**Nederland**
Gilead Sciences Netherlands B.V.
Tel: + 31 (0) 20 718 3698
Deutschland
Gilead Sciences GmbH
Tel: + 49 (0) 89 899890-0

Eesti
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Ελλάδα
Gilead Sciences Ελλάς Μ.Ε.Π.Ε.
Τηλ: + 30 210 8930 100

España
Gilead Sciences, S.L.
Tel: + 34 91 378 98 30

France
Gilead Sciences
Tél: + 33 (0) 1 42 73 70 70

Ireland
Gilead Sciences Ltd
Tel: + 44 (0) 1223 897555

Ísland
Gilead Sciences Sweden AB
Sími: + 46 (0) 8 5057 1849

Italia
Gilead Sciences S.r.l.
Tel: + 39 02 439201

Κύπρος
Gilead Sciences Ελλάς Μ.Ε.Π.Ε.
Τηλ: + 30 210 8930 100

Latvija
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Lietuva
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Norge
Gilead Sciences Sweden AB
Tlf: + 46 (0) 8 5057 1849

Österreich
Gilead Sciences GesmbH
Tel: + 43 1 260 830

Polska
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Portugal
Gilead Sciences, Lda.
Tel: + 351 21 7928790

România
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Slovenija
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Slovenská republika
Gilead Sciences International Ltd
Tel: + 44 (0) 20 7136 8820

Suomi/Finland
Gilead Sciences Sweden AB
Puh/Tel: + 46 (0) 8 5057 1849

Sverige
Gilead Sciences Sweden AB
Tel: + 46 (0) 8 5057 1849

United Kingdom
Gilead Sciences Ltd
Tel: + 44 (0) 1223 897555

This leaflet was last approved in

Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu/.